Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

Vera Eremina; Susan E. Quaggin

doi:10.1016/j.semnephrol.2010.09.006

Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

Vera Eremina, Susan E. Quaggin^*

^*Corresponding author for this work

Medicine, Nephrology Division

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.

Original language	English (US)
Pages (from-to)	582-590
Number of pages	9
Journal	Seminars in nephrology
Volume	30
Issue number	6
DOIs	https://doi.org/10.1016/j.semnephrol.2010.09.006
State	Published - Nov 2010

Keywords

Anti-VEGF therapy
Endothelial cells
Glomerulus
TMA

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.semnephrol.2010.09.006

Cite this

@article{8a87f557233e4678a48440ba6bf5ddb1,

title = "Biology of anti-angiogenic therapy-induced thrombotic microangiopathy",

abstract = "Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.",

keywords = "Anti-VEGF therapy, Endothelial cells, Glomerulus, TMA",

author = "Vera Eremina and Quaggin, {Susan E.}",

note = "Funding Information: S.E.Q. is the recipient of the Gabor-Zellerman Chair in Renal Research and a Canadian Research Chair Tier II. This work was supported by Canadian Institutes of Health Research MOP-62931 , Canadian Institutes of Health Research MOP-77756 , and the Terry Fox Foundation Program Project grant #16002 . ",

year = "2010",

month = nov,

doi = "10.1016/j.semnephrol.2010.09.006",

language = "English (US)",

volume = "30",

pages = "582--590",

journal = "Seminars in Nephrology",

issn = "0270-9295",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

AU - Eremina, Vera

AU - Quaggin, Susan E.

N1 - Funding Information: S.E.Q. is the recipient of the Gabor-Zellerman Chair in Renal Research and a Canadian Research Chair Tier II. This work was supported by Canadian Institutes of Health Research MOP-62931 , Canadian Institutes of Health Research MOP-77756 , and the Terry Fox Foundation Program Project grant #16002 .

PY - 2010/11

Y1 - 2010/11

N2 - Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.

AB - Anti-vascular endothelial growth factor (VEGF) agents are an important component in the treatment of many solid tumors. As the indications for these targeted therapies grow, the expected number of patients to receive these drugs will increase exponentially. Despite the great promise, serious toxicities may arise. Here, we discuss the incidence, pathogenesis, and management of proteinuria and renal insufficiency associated with this class of drugs.

KW - Anti-VEGF therapy

KW - Endothelial cells

KW - Glomerulus

KW - TMA

UR - http://www.scopus.com/inward/record.url?scp=78649932949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649932949&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2010.09.006

DO - 10.1016/j.semnephrol.2010.09.006

M3 - Article

C2 - 21146123

AN - SCOPUS:78649932949

SN - 0270-9295

VL - 30

SP - 582

EP - 590

JO - Seminars in Nephrology

JF - Seminars in Nephrology

IS - 6

ER -

Biology of anti-angiogenic therapy-induced thrombotic microangiopathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this